The results indicate that in vivo exposure to MPS NPs caused more damage to systemic immunity than that of Col NPs through the dysregulation of the spleen. The results for in vivo data are inconsistent with those for in vitro data, which show lower cytotoxicity for MPS NPs. These results suggest the importance of verifying biocompatibility both in vitro and in vivo during the design of new nanomaterials.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: